Literature DB >> 1475753

Vitrectomy in the management of diabetic eye disease.

T Ho1, W E Smiddy, H W Flynn.   

Abstract

Vitrectomy techniques including endolaser photocoagulation allow visual rehabilitation in many eyes that are otherwise untreatable. Discerning the indications and timing for diabetic vitrectomy is increasingly important as the treatment of complications of diabetic retinopathy continues to undergo modification and redefinition. The most common indications for diabetic vitrectomy include: 1) severe nonclearing vitreous hemorrhage; 2) traction retinal detachment recently involving the macula; 3) combined traction and rhegmatogenous detachment; 4) progressive fibrovascular proliferation; and 5) rubeosis iridis and vitreous hemorrhage for eyes in which the media opacity has prevented adequate laser photocoagulation. Other less common indications in selected cases include dense premacular hemorrhage, ghost cell glaucoma, macular edema with premacular traction, cataract preventing treatment of severe, proliferative diabetic retinopathy, anterior hyaloidal fibrovascular proliferation, and fibrinoid syndrome with retinal detachment. The rationale and surgical objectives are discussed and results are summarized.

Entities:  

Mesh:

Year:  1992        PMID: 1475753     DOI: 10.1016/0039-6257(92)90137-i

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  21 in total

1.  Macular morphologic findings on optical coherence tomography after microincision vitrectomy for proliferative diabetic retinopathy.

Authors:  Tomoaki Murakami; Akihito Uji; Ken Ogino; Noriyuki Unoki; Shin Yoshitake; Yoko Dodo; Takahiro Horii; Kazuaki Nishijima; Nagahisa Yoshimura
Journal:  Jpn J Ophthalmol       Date:  2015-05-09       Impact factor: 2.447

2.  Perfluorocarbon in vitreoretinal surgery and preoperative bevacizumab in diabetic tractional retinal detachment.

Authors:  J Fernando Arevalo; Martin A Serrano; Juan D Arias
Journal:  World J Diabetes       Date:  2014-10-15

Review 3.  Current approaches to the management of diabetic retinopathy and diabetic macular oedema.

Authors:  Francesco Boscia
Journal:  Drugs       Date:  2010-11-12       Impact factor: 9.546

Review 4.  [Surgical treatment of diabetic retinopathy and maculopathy].

Authors:  A M Joussen; H Llacer; J Mazciewicz; B Kirchhof
Journal:  Ophthalmologe       Date:  2004-12       Impact factor: 1.059

5.  Targeting Neovascularization in Ischemic Retinopathy: Recent Advances.

Authors:  Mohamed Al-Shabrawey; Mohamed Elsherbiny; Julian Nussbaum; Amira Othman; Sylvia Megyerdi; Amany Tawfik
Journal:  Expert Rev Ophthalmol       Date:  2013-06

6.  Panretinal photocoagulation induces pro-inflammatory cytokines and macular thickening in high-risk proliferative diabetic retinopathy.

Authors:  Masahiko Shimura; Kanako Yasuda; Toru Nakazawa; Toshiaki Abe; Takashi Shiono; Tomohiro Iida; Taiji Sakamoto; Kohji Nishida
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-07-29       Impact factor: 3.117

7.  Life expectancy of diabetic patients undergoing vitreous surgery.

Authors:  H Helbig; U Kellner; N Bornfeld; M H Foerster
Journal:  Br J Ophthalmol       Date:  1996-07       Impact factor: 4.638

8.  Panretinal-Photocoagulation before Pars Plana Vitrectomy Influences Vitreous Level of Interleukin-6 but not of Vascular Endothelial Growth Factor in Patients with Diabetic Retinopathy.

Authors:  Masahiko Shimura; Kanako Yasuda; Toru Nakazawa; Takashi Shiono; Kohji Nishida
Journal:  Int J Biomed Sci       Date:  2007-03

9.  Individualised treatment of proliferative diabetic retinopathy: optimal surgical timing improves long-term outcomes.

Authors:  Stefano Zenoni; Natalia Comi; Piero Fontana
Journal:  EPMA J       Date:  2010-03-10       Impact factor: 6.543

10.  Faster recovery after 25-gauge microincision vitrectomy surgery than after 20-gauge vitrectomy in patients with proliferative diabetic retinopathy.

Authors:  Tatsuhiko Sato; Kazuyuki Emi; Hajime Bando; Toshihide Ikeda
Journal:  Clin Ophthalmol       Date:  2012-11-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.